Madam Speaker, I thank the hon. member for Shefford for the question. I will answer the first part of the question in French, and then I will switch to English to talk about the more technical aspects.
I agree that some countries should be removed from the list of countries that are considered when setting average prices.
I will switch to English, because this is a technical answer.
The PMPRB is also looking at quality-adjusted life year, which basically says, “this is the value of every single year of a life”, to determine whether it should finance that medication.
I am not saying that national pharmacare may not work. I am saying that it would likely fail and make things worse by limiting access to expensive medication at the beginning. These are real people, with real problems and real families, who will have to go overseas to get the medications they need.